Dobutamine Hydrochloride
Overview
Dobutamine Hydrochloride is a synthetic catecholamine derivative developed as a selective β1-adrenergic receptor agonist. It was first synthesized in the 1970s as an alternative to dopamine for cardiovascular support. The compound is structurally related to dopamine but has been modified to enhance cardiac selectivity while minimizing peripheral vascular effects. As a pharmaceutical active ingredient, it is commonly formulated as an injectable solution for hospital use. The hydrochloride salt form improves stability and solubility compared to the free base. Regulatory agencies worldwide classify it as a prescription-only medication due to its potent cardiovascular effects.
Physical and Chemical Properties
The compound presents as a white crystalline powder with good stability under recommended storage conditions. Its hydrochloride salt form demonstrates excellent water solubility (approximately 50 mg/mL at room temperature), making it suitable for intravenous administration. The powder is hygroscopic and requires protection from moisture during storage. Chemically, dobutamine hydrochloride is sensitive to oxidation and light exposure, which can lead to degradation products. Solutions turn pink upon decomposition. The molecule contains a chiral center, with the (±)-erythro form being the pharmacologically active racemic mixture used clinically. The crystalline structure has been characterized by X-ray diffraction studies.
Main Applications
In clinical practice, dobutamine hydrochloride is primarily employed as a short-term treatment for acute decompensated heart failure, particularly in hospital intensive care units. It increases myocardial contractility and cardiac output without significantly raising peripheral vascular resistance, making it preferable to dopamine in many cases. The pharmaceutical is also used in cardiac stress testing (dobutamine stress echocardiography) to evaluate coronary artery disease. Off-label applications include treatment of cardiogenic shock and as an adjunct in septic shock management. Therapeutic doses typically range from 2.5-40 μg/kg/min via continuous IV infusion, with effects appearing within 2-10 minutes of administration.
Safety and Storage
As a potent cardiovascular agent, dobutamine hydrochloride requires careful handling by trained medical personnel. The drug can cause significant adverse effects including tachycardia, hypertension, ventricular arrhythmias, and myocardial ischemia. Continuous ECG and blood pressure monitoring are mandatory during administration. For storage, the powder should be kept in tightly sealed containers under refrigeration (2-8°C) with desiccants. Prepared solutions are stable for 24 hours at room temperature or 48 hours if refrigerated. The compound should be protected from light exposure during both storage and administration. Disposal should follow pharmaceutical waste regulations.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing dobutamine hydrochloride should prioritize suppliers with certified GMP compliance and proper documentation of synthesis pathways. Key quality parameters include chromatographic purity (>99%), low heavy metal content (<10 ppm), and absence of genotoxic impurities. Bulk purchases typically range from 1kg to 50kg quantities, with pricing varying based on volume and purity specifications. Due to the controlled nature of the substance, buyers must ensure proper import/export licenses are obtained. Lead times can extend to 4-6 weeks for international shipments requiring cold chain logistics. Quality audits of API manufacturers are recommended for long-term supply agreements.